Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).

被引：0

作者：

Muller, Martin C.

Baccarani, Michele

Deininger, Michael W. N.

Guilhot, Francois

Hochhaus, Andreas

Hughes, Timothy P.

Shah, Neil P.

Talpaz, Moshe

Lustgarten, Stephanie

Rivera, Victor M.

Clackson, Timothy Piers

Haluska, Frank G.

Cortes, Jorge E.

机构：

[1] Univ Med Mannheim, Mannheim, Germany

[2] S Orsola Malpighi Univ Hosp, Bologna, Italy

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France

[5] Jena Univ Hosp, Jena, Germany

[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[7] Univ Adelaide, Adelaide, SA, Australia

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Univ Michigan, Ann Arbor, MI 48109 USA

[10] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7053

引用

页数：4

共 50 条

[21] 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study
Deininger, Michael
Apperley, Jane
Arthur, Christopher Kevin
Chuah, Charles
Hochhaus, Andreas
de Lavallade, Hugues
Lipton, Jeffrey
Lomaia, Elza
McCloskey, James
Maness, Lori
Mauro, Michael
Moiraghi, Beatriz
Pavlovsky, Carolina
Rosti, Gianantonio
Rousselot, Philippe
Sutton, Maria Undurraga
Ren, Xiaowei
Vorog, Alexander
Kantarjian, Hagop
Cortes, Jorge
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S354
[22] Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML
Cortes, Jorge E.
Apperley, Jane
Hochhaus, Andreas
Mauro, Michael J.
Rousselot, Philippe
Sacha, Tomasz
Talpaz, Moshe
Chuah, Charles
Lipton, Jeffrey H.
Deininger, Michael W.
Schiffer, Charles A.
Maness, Lori J.
McCloskey, James K.
Gutierrez, Valentin Garcia
de Lavallade, Hugues
Etienne, Gabriel
Lu, Vickie
Srivastava, Shouryadeep
Rosti, Gianantonio
BLOOD, 2020, 136
[23] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
Lipton, Jeffrey H.
Chuah, Charles
Guerci-Bresler, Agnes
Rosti, Gianantonio
Simpson, David
Assouline, Sarit
Etienne, Gabriel
Nicolini, Franck E.
Le Coutre, Philipp
Clark, Richard
Stenke, Leif
Andorsky, David
Oehler, Vivian
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Haluska, Frank G.
Baccarani, Michele
Cortes, Jorge E.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop M.
Shah, Neil P.
Talpaz, Moshe
Deininger, Michael W.
BLOOD, 2014, 124 (21)
[24] Impact of Treatment Strategies on Clinical Outcomes In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients In Canada
Cribb, Nancy
Merali, Tazmin
Donato, Bonnie M. K.
BLOOD, 2010, 116 (21) : 1063 - 1063
[25] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u)
Kantarjian, Hagop
Flinn, Ian W.
Goldberg, Stuart
Bunworasate, Udomsak
Zanichelli, Maria Aparecida
Nakamae, Hirohisa
Hughes, Timothy P.
Hochhaus, Andreas
Saglio, Giuseppe
Woodman, Richard Charles
Blakesley, Rick E.
Kemp, Charisse N.
Kalaycio, Matt E.
Larson, Richard A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[26] Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Conlan, Maureen
Guilhot, Francois
Deininger, Mochael W.
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop M.
Shah, Neil P.
BLOOD, 2015, 126 (23)
[27] LONGER-TERM FOLLOW-UP OF THE IMPACT OF BASELINE (BL) MUTATIONS ON PONATINIB RESPONSE AND END OF TREATMENT (EOT) MUTATION ANALYSIS IN PATIENTS (PTS) WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
Deininger, M. W.
Shah, N. P.
Cortes, J. E.
Kim, D. W.
Nicolini, F. E.
Talpaz, M.
Baccarani, M.
Mueller, M. C.
Li, J.
Lustgarten, S.
Clackson, T.
Turner, C. D.
Haluska, F. G.
Hodgson, G.
Rivera, V. M.
Guilhot, F.
Kantarjian, H. M.
Soverini, S.
Hochhaus, A.
Hughes, T. P.
Branford, S.
HAEMATOLOGICA, 2014, 99 : 533 - 533
[28] Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)
Deininger, Michael W.
Shah, Neil P.
Cortes, Jorge E.
Kim, Dong-Wook
Nicolini, Franck E.
Talpaz, Moshe
Baccarani, Michele
Muller, Martin C.
Li, Jin
Lustgarten, Stephanie
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Hodgson, Graeme
Rivera, Victor M.
Guilhot, Francois
Goldman, John M.
Kantarjian, Hagop M.
Soverini, Simona
Hochhaus, Andreas
Hughes, Timothy P.
Branford, Susan
BLOOD, 2013, 122 (21)
[29] SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD-OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB
Stellato, D.
McGarry, L.
Huang, H.
Hastings, S.
Delea, T.
HAEMATOLOGICA, 2017, 102 : 434 - 434
[30] Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
Stellato, Daniel R.
McGarry, Lisa
Huang, Hui
Hastings, Shaina
Delea, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →